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Objectives: Gender and ethnicity are factors affecting the incidence and severity of vascular disease as well as subsequent
treatment outcomes. Although well studied in other fields, balanced enrollment of patients with relevant demographic
characteristics in vascular surgery randomized controlled trials (RCTs) is not well known. This study describes the
reporting of gender and ethnicity data in vascular surgery RCTs and analyzes whether these studies adequately represent
our diverse patient population.
Methods: We conducted a retrospective review of United States-based RCTs from 1983 through 2007 for three broadly
defined vascular procedures: aortic aneurysm repair (AAR), carotid revascularization (CR), and lower extremity
revascularization (LER). Included studies were examined for gender and ethnicity data, study parameters, funding
source, and geographic region. The Nationwide Inpatient Sample (NIS) database was analyzed to obtain group-specific
procedure frequency as an estimate of procedure frequency in the general population.
Results:We reviewed 77 studies, and 52met our inclusion criteria. Only 85% reported gender, and 21% reported ethnicity.
Reporting of ethnicity was strongly associated with larger (>280 participants), multicenter, government-funded trials
(P < .001 for all). Women are disproportionately under-represented in RCTs for all procedure categories (AAR, 9.0% vs
21.5%; CR, 30.0% vs 42.9%; LER, 22.4% vs 41.3%).Minorities are under-represented in AAR studies (6.0% vs 10.7%) and
CR studies (6.9% vs 9.5%) but are over-represented in LER studies (26.0% vs 21.8%, P < .001 for all).
Conclusions: Minority ethnicity and female gender are under-reported and under-represented in vascular surgery RCTs,
particularly in small, non-government-funded and single-center trials. The generalizability of some trial results may not
be applicable to these populations. Greater effort to enroll a balanced study population in RCTs may yield more broadly
applicable results. ( J Vasc Surg 2009;50:349-54.)Evidence-based medicine has revolutionized health
care with the increased use of rigorous scientific analysis to
address clinical questions. As a result, greater appreciation
of the relative strengths of different types of clinical evi-
dence has also affected the pursuit of new clinical analyses.
Properly designed and conducted randomized controlled
trials (RCTs) are considered the highest level of evidence
(Level I) available to guide clinical practice. The strength of
the RCT lies in the randomization of patients to treatment
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doi:10.1016/j.jvs.2009.01.012options, because randomization controls the effect of
known and unknown confounders. As with all clinical
studies, one limitation of the RCT is that results may not be
applicable to patients who are under-represented in the
study sample.
Disparities exist between gender and between race/
ethnicity with regard to the prevalence, presentation, and
outcome of vascular disease. There is evidence that African
Americans (AAs) andHispanic Americans (HAs), for exam-
ple, have a higher prevalence of cardiovascular risk factors,
including hypertension, diabetes,1-4 and peripheral arterial
disease (PAD) as measured by the ankle-brachial index
compared with whites.1,5,6 These disparities also extend to
disease severity and treatment outcomes. AAs and HAs
have more severe PAD as well as subsequent worse out-
comes of bypass grafting and greater need for amputation
compared with whites.3,4,7 Furthermore, AAs have higher
risk-adjusted mortality after cardiac and vascular proce-
dures, including coronary artery bypass grafting, aortic
aneurysm repair (AAR), and carotid endarterectomy com-
pared with HAs and whites.8 Gender differences in presen-
tation and outcome of vascular disease have also been
demonstrated, with women having a higher ratio of emer-
gency AAR than men,9 and higher mortality rates, longer
length of stay, and increased discharge to a nursing facility
after both elective and emergency AAR.10 Both women
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after lower extremity revascularization (LER).11
Clinical studies should account for these gender and
ethnicity disparities in vascular disease. Enrollment of a
representative patient population in RCTs is important to
broaden the generalizability of the results. Other special-
ties, particularly medical oncology, have documented under-
representation of women and minorities in RCTs.12,13
However, little information is available to assess whether
the study populations in vascular surgery in RCTs are
representative of the patients at risk for vascular disease.
The disparity in enrollment into studies and trials by
gender and ethnicity was addressed in the National Insti-
tutes of Health (NIH) Revitalization Act of 1993, titled,
“Women and Minorities as Subjects in Clinical Re-
search.”14,15 This act mandated representative inclusion of
women and minorities as subjects in clinical research. It
further specified that, particularly in diseases where patho-
physiology or treatment may differ depending on gender or
ethnicity, women and ethnic minorities must be adequately
represented to detect differences in end points. Practically
speaking, this act significantly affects clinical research
through its implications for trial design, subject recruit-
ment, and study documentation. Implicit in these man-
dates are complete reporting of gender and ethnicity in all
clinical research, even if adequate representation cannot be
achieved.
We hypothesized that there is disproportionately low
enrollment of women and ethnicminorities in RCTs for the
treatment of vascular disease in the United States (U.S.).
To evaluate our hypothesis, we initiated a retrospective
analysis of published RCTs for three common vascular
surgery procedures: AAR, carotid revascularization (CR),
and LER. We analyzed the reporting of gender and ethnic-
ity in these RCTs and compared the enrolled population
mix with a contemporary estimate of procedure frequency
based on a nationwide inpatient care database.
METHODS
Study design. In August 2007 we conducted an elec-
tronic search of RCTs published during the last 25 years
using the Medline and Cochrane Clinical Trials databases.
Our three categories of vascular procedure (AAR, CR and
LER) were intended to be broadly inclusive to maximize
the number of clinically relevant studies.
The Medline database was searched for articles pub-
lished in English between 1983 and August 2007 using a
combined keyword and medical subject heading (MeSH)
strategy. The term randomized controlled trial was inclu-
sively paired (and) with an array of search terms related to
the three vascular procedures. For AAR this included aortic
aneurysm, thoracic aneurysm, and abdominal aneurysm.
For CR this included carotid, carotid stenosis, and carotid
endarterectomy. For LER this included claudication, pe-
ripheral vascular disease, critical limb ischemia, and lower
extremity bypass.
Similarly, the Cochrane Randomized Controlled Trial
Database was searched for studies conducted between1983 and 2007 that included the keywords carotid, aortic,
or lower extremity. Finally, six Cochrane Review articles
generated by a generalized Cochrane Database search of
these terms were reviewed for relevant RCTs (Appendix 1,
online only).
The resulting articles were individually screened to
include only U.S. RCTs that included a vascular surgical or
endovascular procedure as a component of the trial design.
Studies that contained multiple procedures were included
in the pooled analysis of gender and ethnicity reporting;
however, these multiple procedure trials only included
procedures typically performed by a vascular surgeon. For
example, a trial involving LER and AAR would be in-
cluded, but a trial involving AAR and aortic root repair
would be excluded.
All included studies were evaluated for the reporting of
the gender and ethnicity of their participants. Studies that
reported gender and ethnicity were further analyzed for the
proportion of women and minority race/ethnicity partici-
pants enrolled. The number enrolled, the funding source of
the research, the number of centers enrolling participants,
and the publication year of each study was also recorded.
For the purposes of our evaluation, “ethnic minority” was
defined as an enrolled patient other than a “white” or
“non-Hispanic white” as reported in each study.
Nationwide Inpatient Sample database. The Na-
tionwide Inpatient Sample (NIS) database is the largest
all-payer inpatient care database publicly available in the
United States, It contains data from 5 to 8 million hospital
stays from approximately 1000 hospitals representing a 20%
stratified sample of U.S. hospitals. The 2004 and 2005 NIS
databases (the two most current years available) were que-
ried for combined diagnoses and procedures for each of the
three categories of AAR, CR, and LER. The patient sample
with a pertinent code for each diagnosis (aortic aneurysm,
carotid stenosis, PAD) was paired with an appropriate
procedure code for AAR, CR, or LER. As a result, only
patients with a diagnosis of aortic aneurysm, carotid steno-
sis, or PAD who underwent treatment for that diagnosis
were included in the data set (Appendix 2, online only).
The resulting raw 20% patient sample for each proce-
dure category was subsequently stratified by gender and
race/ethnicity, yielding a relative frequency estimate for
both categories. These frequency estimates served as the
expected demographic ratios and were then compared with
the demographic data from RCTs that reported demo-
graphic data for gender or race/ethnicity, or both. TheNIS
data collection and stratification was completed using SAS
9.1 software (SAS Institute Inc, Cary, NC).
Statistical analysis. The reporting of gender or race/
ethnicity, or both, was evaluated as a binomial variable
using the Fisher exact test to evaluate the association be-
tween demographic reporting and study characteristics.
These characteristics include publication year, number of
centers enrolling participants (single-center or multi-
center), funding source, and study size. Funding sources
were dichotomized between government-funded studies
such as National Institutes of Health and Veterans Affairs
tremi
tremi
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private institutions, and nonspecified sources. Study size
was dichotomized into “large” and “small” subgroups
according to enrollment above or below the mean enroll-
ment number (280 patients) among all trials. Studies that
reported enrollment data by gender or race/ethnicity, or
both, were further evaluated by comparison with the pro-
cedure frequency by gender and race/ethnicity, as esti-
mated from theNIS database using the Fisher exact test. An
  0.05, corresponding to a P  .05, was considered
statistically significant. All statistical analyses were per-
formed using SAS 9.1 software.
RESULTS
The initial literature search yielded 77 studies that were
individually reviewed for project inclusion. Of these, 25
were excluded because of geographic (outside the United
States) and surgical procedural characteristics (nonvascular
surgical procedures), leaving 52 studies for our final analy-
sis. These studies were divided by category of diagnosis (11
AAR, 18 CR, 13 LER, and 10 multiprocedure) and evalu-
ated for the reporting of gender and ethnicity in the study
samples (Appendix 3, online only). The 52 studies random-
ized 14,604 participants. Each RCT enrolled amean of 280
individuals (median, 100; range, 9-2226). Four studies
enrolled 1000 individuals. Included studies were pub-
lished between 1983 and 2007, with a median publication
year of 1998 and mode for publication year of 1997 (9
studies).
Gender and ethnicity reporting. The randomized
sample found 44 of 52 studies (85%) had reported the
gender of participants. The 12 government-funded studies
Table I. Data summary of randomized controlled trials th
Procedure
category Studies
Reporting
gender,
No. (%)
Reporting
ethnicity,
No. (%)
Subjects,
No.
De
gend
AAR 11 9 (81.8) 1 (9.1) 1744 16
CR 18 16 (88.9) 4 (22.2) 6576 63
LER 13 10 (76.9) 5 (38.5) 5044 46
Multi 10 9 (90.0) 1 (10.0) 1239 1
Total 52 44 (84.6) 11 (21.1) 14603 13,7
AAR, Aortic aneurysm repair; CR, carotid revascularization; LER, lower ex
Table II. Data summary of Nationwide Inpatient Sample
Procedure
category Procedures, No.
Designated
gender, No. (%)
AAR 14,288 14,267 (99.9)
CR 48,397 48,344 (99.9)
LER 18,556 18,534 (99.9)
Multiple NA NA
Total 81,241 81,145 (99.9)
AAR, Aortic aneurysm repair; CR, carotid revascularization; LER, lower exand the 12 large studies (280 subjects) reported genderin their demographics. Both of these study characteristics
showed a trend toward significance (P  .17) when com-
pared with non-government-funded studies and small
studies (280 subjects), respectively. No significant report-
ing differences were found between single center (N 17) or
multicenter trials. Because the NIH mandated inclusion of
race andgender data starting in 1994, the publication yearwas
also evaluated for differences of gender reporting. This dem-
onstrated no difference between the frequency of gender
reporting before or after 1994 (P  .99, N  41 for post-
1994 studies). To account for a delay between trial enrollment
and publication, gender reporting was also compared in five
separate analyses using years 1995 through 1999. Likewise,
no significant difference in reporting was found for any of the
publication years evaluated.
Race or ethnicity was reported in 11 of 52 studies.
Reporting of ethnicity was associated with large, multi-
center trials and government-funded trials (P  .001 for
all). Ethnicity reporting was not associated with publication
year of the study for any single year between 1994 and
1999. Aggregate reporting, enrollment, and estimated pro-
cedure frequency data are summarized in Tables I and II.
Enrollment comparisons. RCTs of only one proce-
dure (N  42) and also reporting gender (N  35) or
ethnicity (N  10), or both, were further analyzed for
representative enrollment by comparison with nationwide
procedural rates from the NIS database. According to the
NIS, women comprised approximately 21.5% of AAR,
42.9% of CR, and 41.3% of LER procedures in 2004 to
2005. In contrast, the RCTs showed women represented
9.0% of AAR, 30% of CR, and 22.4% of LER participants.
In each of these procedure categories, women were signif-
ported and enrollment by gender and ethnicity
ted
. (%)
Women, No. (% of
total designated)
Designated
ethnicity, No. (%)
Minorities, No.
(% of total
designated)
5.7) 151 (9.0) 1136 (65.1) 68 (6.0)
6.6) 1907 (30.0) 4400 (66.9) 305 (6.9)
2.3) 1044 (22.4) 2979 (59.1) 776 (26.0)
5.3) 156 (14.8) 99 (8.0) 14 (14.1)
4.0) 3258 (23.7) 8614 (59.0) 1163 (13.5)
ty revascularization.
4-2005) procedure estimates by gender and ethnicity
men, No. (% of
al designated)
Designated
ethnicity, No. (%)
Minorities, No.
(% of total
designated)
3069 (21.5) 10,676 (74.7) 1138 (10.7)
0,745 (42.9) 35,357 (73.0) 3354 (9.5)
7666 (41.3) 13,502 (72.8) 2941 (21.8)
NA NA NA
1,480 (38.8) 59,535 (73.3) 7433 (12.5)
ty revascularization; NA, not applicable.at re
signa
er No
69 (9
53 (9
54 (9
057(8
33 (9(200
Wo
tot
2
3icantly under-represented in RCTs compared with the es-
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for all, Fig, A).
In the NIS, minorities comprised approximately 10.7%
of AAR, 9.5% of CR, and 21.8% of LER procedures in
2004 to 2005. In contrast, minorities represented 6.0%
of AAR, 6.9% of CR, and 26.0% of LER subjects in
RCTs. In AAR and CR studies, minorities were signifi-
cantly under-represented (P  .001). Studies of LER en-
rolled a higher proportion of minorities compared with the
estimated procedure frequency (P  .001; Fig, B).
Six of the single-procedure RCTs in our study were
from the VA health care system (1 for AAR, 2 for CR, and
3 for LER). These studies tended to be larger in enrollment
(median, 598; range, 189-1136), and all reported gender
demographic data. Because of the inherent gender imbal-
ance in the VA population, we performed a secondary
gender enrollment analyses with these VA RCTs excluded.
This demonstrated female enrollment of 26.4% in AAR
studies vs 21.5% of AAR procedures estimated from NIS,
33.3% in CR studies vs 42.9% of CR procedures, and 37.0%
in LER studies vs 41.3% of LER procedures. These com-
parisons demonstrate that non-VA RCTs of AAR enrolled
significantly more women than the estimated procedure
frequency from the NIS (P  .008), but women remained
under-represented in non-VA studies of CR and LER (P
.0001) even though the gap between enrollment and esti-
mated procedure frequency narrowedmarkedly. The exclu-
sion of VA-based trials from the evaluation of minority
race/ethnicity enrollment was also performed and demon-
strated similar percentages to procedure-specific enroll-
ment in all of the available studies related to CR and LER.
Exclusion of VA-based trials from the AAR studies left us
with no studies that reported race/ethnicity demographic
Fig. Proportion of participants enrolled in vascular surgery ran-
domized controlled trials (RCT) compared with estimated pro-
portion of patients receiving procedures from the Nationwide
Inpatient Sample (NIS) for (A) female gender and (B) minority
ethnicity. **P  .001 by 2.data.DISCUSSION
Vascular surgeons treat a diverse patient population,
and Level I evidence derived from RCTs guides the stan-
dard of surgical care based on the representative sampling
of that population. This study shows that complete demo-
graphic reporting of gender and race/ethnicity is absent
from a large portion of the vascular surgery RCTs con-
ducted in the United States. Complete demographic re-
porting, particularly for ethnicity, was associated with
larger, multicenter or government-funded trials, or both.
There does not appear to be significant increases in report-
ing over time, particularly in the years after the NIH
Revitalization Act of 1993. Among studies reporting gen-
der and ethnicity data, women were significantly under-
represented in RCTs for AAR, LER, and CR procedures,
whereas ethnic minorities were under-represented in RCTs
involving AAR and CR.
The under-reporting and under-representation of
women and minorities occurs in a broad array of clinical
research across multiple specialties. Even in specialties with
known health disparities between gender and ethnicity,
such as in diabetes, cardiac disease, HIV, and cancer, there
is persistent under-reporting of complete demographic
data in clinical research.16 There is also a demonstrated
under-representation of women and minorities in clinical
trials and in statistical models aimed at better understand-
ing the disparities in disease prevalence and outcomes.17
Oddone et al18 evaluated trials containing an invasive arm
and demonstrated that most enrolled fewer minority pa-
tients than expected. Interestingly, this same study showed
that most trials for diseases with disproportionate minority
prevalence (diabetes, hypertension, end-stage renal disease)
enrolled more minorities than expected.18 As we have
noted, PAD is more prevalent in AAs and HAs. As such,
our study corroborates the Oddone findings in RCTs of
LER, where minority enrollment exceeded estimated
procedure frequency. A potential explanation for this
over-representation may be that many RCTs occur at large
academic institutions that already care for a larger number
of minority patients. Thus, the pool of trial participants is
already over-represented in these institutions.
Significant consideration has been given to the causes
of under-representation of minorities and women in RCTs.
One long-held belief is that ethnic minorities are less will-
ing to participate in human and clinical research, attributed
to a mistrust of the medical and scientific community
stemming from the Tuskegee syphilis and other similar
experiments that have been widely publicized.19 This no-
tion has become increasingly controversial, however, be-
cause multiple recent studies have demonstrated equivalent
willingness of individuals to participate in clinical trials
regardless of ethnicity.20 Despite this, reports indicate that
minorities are more likely to believe that they had been
previously treated in a trial without their consent.21 This
suggests a persistent element of differing expectations and
mistrust that needs to be overcome.
JOURNAL OF VASCULAR SURGERY
Volume 50, Number 2 Hoel et al 353In contrast, women, particularly those of child-bearing
age, have a long history of being excluded from RCTs.
Historically, this partly stems from a desire to limit the
exposure of women of child-bearing age to experimental
treatments.22 However, with the recognition that gender is
an important variable in the manifestation of disease and in
the response to treatment, there has been significant effort
toward balanced enrollment by gender into clinical trials.
That there remains a persistent disparity in representation
of women in a broad spectrum of clinical trials suggests the
interplay of multiple subtle factors, both in society and in
clinical trial design and execution.23
This study has several limitations. First, race/ethnicity
is self-reported in RCTs and in the NIS database. Further-
more, race/ethnicity is a complex topic, with significant
contributions from the fields of genetics, sociology, anthro-
pology, and history. Not all minorities share similar back-
grounds, making broad categorization difficult, especially
considering immigration patterns in the United States.
Despite these inherent difficulties in defining race/ethnic-
ity, studies should at least try to report this important
demographic in some manner. Presumably, gender is a
more straightforward demographic variable to evaluate;
yet, many studies do not even report these data. The studies
not reporting gender or ethnicity may possibly have over-
representation of these groups, and thus, the overall RCT
enrollment distribution may be appropriate. However,
when important demographic information is not available,
no meaningful conclusions can be made.
Second, appropriate trial design may necessitate exclu-
sion of portions of the population that have significant
minority or gender representation. For example, end-stage
renal disease is frequently a component of the exclusion
criteria of vascular surgery RCTs and it disproportionately
affects AAs.24,25 As such, the goal of developing accurate
end pointmeasurementmay have the unintended, and poten-
tially unavoidable, consequence of under-representing spe-
cific patient populations.
Third, enrollment results are not entirely under the
control of researchers. Very few RCTs can draw enrollment
from a nationally representative patient population. Even
for multicenter studies, the local institutions conducting
the trial may have distinct referral patterns. In particular,
the VA patient population is not representative of the U.S.
population in that it under-represents women. However,
many high-quality vascular surgery RCTs that guide clinical
decision making come from VA collaborations. Our suba-
nalysis that excluded VA studies demonstrated attenuated
disparities in enrollment. A more balanced incorporation of
the VA population into the main analysis would require
access to VA population and procedural data that were not
available to us. Furthermore, with the increasing military
enlistment of women and minorities in recent decades, the
current veteran population may be more demographically
similar to the entire U.S. population than in previous times.
Finally, the limited numbers of studies available in each
category do not lend themselves to more sophisticated
statistical measures. Because many of the parameters exam-ined were strongly co-associated (eg, large trials and mul-
ticenter trials consisted of overlapping groups), multivari-
ate logistic regression did not yield interpretable results and
were therefore left out of this analysis.
CONCLUSIONS
Despite these limitations, this study clearly demon-
strates under-reporting of gender and race/ethnicity as well
as disparities in the enrollment of women and minorities in
vascular surgery RCTs. This has significant implications for
the interpretation and generalizability of these studies to
the overall population. Recognition of these limitations
may help surgeons assimilate other studies with better
representation for their patient population. We do not
imply that the disparities in reporting and enrollment are
intentional; rather, patient concerns, unrecognized bias,
and local population demographics likely contribute to
these disparities. Nevertheless, this issue is highlighted to
promote compliance to NIH regulations in future studies.
Further, in the interest of better understanding our
diverse patient population, we believe these regulations
should extend to all vascular surgery clinical studies, not
just those funded by the NIH. With this recognition,
researchers can focus on identifying and improving barriers
to balanced recruitment and retention appropriate for their
local environment. Such strategies can include focused
recruitment and education about clinical research ethics
and safeguards, recruitment of institutions with intrinsic
minority representation into multi-center trials, and re-
cruitment goals/caps determined by estimates of disease
incidence or procedural frequency.
In summary, gender and ethnicity demographics are
under-reported in RCTs of AAR, CR, and LER. Among
studies with adequate reporting, disparities exist between
the observed distribution of enrolled patients and expected
enrollment as determined by national procedural frequen-
cies. These findings affect the generalizability of RCT re-
sults and should serve as a stimulus to better comply with
NIH clinical research guidelines.
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